Entrada’s commitment to publications & transparency
Entrada is committed to publishing the results of our sponsored research in a transparent, scientifically accurate, and timely manner. Entrada will apply high ethical standards to our publications and presentations and will adhere to recognized industry guidance such as International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals and International Society for Medical Publication Professionals (ISMPP) Good Publication Practice for Communicating Company Sponsored Medical Research.
Past Presentations
-
Endosomal Escape Vehicles (EEV) to Enhance the Functional Delivery of Oligonucleotides in Preclinical Models of Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 2023 MDA Clinical and Scientific Conference
DownloadMar 20, 2023 -
Exon Skipping and Dystrophin Production with a Novel EEV-Conjugated, Exon 45 Skip Amenable PMO in Preclinical Models of DMD
- By: Nelsa Estrella, PhD, Entrada Therapeutics
- At: 2023 MDA Clinical and Scientific Conference
DownloadMar 19, 2023 -
Endosomal Escape Vehicle-Oligonucleotide Conjugates for the Targeted Upregulation and Downregulation of Gene Expression
- By: Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 8th Annual Annual Oligonucleotide & Precision Therapeutics Congress
DownloadMar 14, 2023 -
Development of Endosomal Escape Vehicles (EEV) to Enhance the Functional Delivery of Oligonucleotides
- By: Patrick Dougherty, PhD, Senior Scientist, Entrada Therapeutics
- At: Targeted Intracellular Delivery Summit
DownloadMar 08, 2023 -
Endosomal Escape Vehicles (EEV™) to Enhance the Functional Delivery of Oligonucleotides in Preclinical Models of Neuromuscular Diseases
- By: Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 2nd Annual Solve FSHD Conference
DownloadMar 02, 2023 -
Endosomal Escape Vehicle (EEV) Platform to Enhance the Functional Delivery of Oligonucleotides
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: TIDES EUROPE 2022
DownloadNov 17, 2022 -
Development of Endosomal Escape Vehicles to Enhance the Intracellular Delivery of Oligonucleotides
- By: Patrick Dougherty, PhD, Senior Scientist, Entrada Therapeutics
- At: 2022 Boulder Peptide Symposium
DownloadNov 10, 2022 -
EEV-Conjugated PMO Results in Nuclear Foci Reduction and Aberrant Splicing Correction in Myotonic Dystrophy Cell and Animal Models
- By: Mahasweta Girgenrath, PhD, Head of Cardiovascular and Neuromuscular Therapeutic Areas, Entrada Therapeutics
- At: 27th International Annual Congress of the World Muscle Society (WMS)
DownloadOct 14, 2022 -
Development of a Novel, EEV-Conjugated PMO for Duchenne Muscular Dystrophy
- By: Nerissa Kreher, MD, Chief Medical Officer, Entrada Therapeutics
- At: 27th International Annual Congress of the World Muscle Society (WMS)
DownloadOct 11, 2022 -
A Novel Endosomal Escape Vehicle-Conjugated Oligonucleotide for Myotonic Dystrophy Type 1
- By: Xiulong Mark Shen, PhD, Senior Scientist, Entrada Therapeutics
- At: 18th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
DownloadOct 02, 2022